> Details

Gyöngyösi, Mariann; Hasimbegovic, Ena; Han, Emilie; Zlabinger, Katrin; Spannbauer, Andreas; Riesenhuber, Martin; Hamzaraj, Kevin; Bergler-Klein, Jutta; Hengstenberg, Christian; Kammerlander, Andreas; Kastl, Stefan; Loewe, Christian; Beitzke, Dietrich

Improvement of Symptoms and Cardiac Magnetic Resonance Abnormalities in Patients with Post-Acute Sequelae of SARS-CoV-2 Cardiovascular Syndrome (PASC-CVS) after Guideline-Oriented Therapy

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Improvement of Symptoms and Cardiac Magnetic Resonance Abnormalities in Patients with Post-Acute Sequelae of SARS-CoV-2 Cardiovascular Syndrome (PASC-CVS) after Guideline-Oriented Therapy
  • Contributor: Gyöngyösi, Mariann; Hasimbegovic, Ena; Han, Emilie; Zlabinger, Katrin; Spannbauer, Andreas; Riesenhuber, Martin; Hamzaraj, Kevin; Bergler-Klein, Jutta; Hengstenberg, Christian; Kammerlander, Andreas; Kastl, Stefan; Loewe, Christian; Beitzke, Dietrich
  • imprint: MDPI AG, 2023
  • Published in: Biomedicines
  • Language: English
  • DOI: 10.3390/biomedicines11123312
  • ISSN: 2227-9059
  • Keywords: General Biochemistry, Genetics and Molecular Biology ; Medicine (miscellaneous)
  • Origination:
  • Footnote:
  • Description: <jats:p>Cardiac magnetic resonance (CMR) studies reported CMR abnormalities in patients with mild–moderate SARS-CoV-2 infection, suggesting ongoing myocardial inflammation. Patients (n = 278, 43 ± 13 years, 70.5% female) with post-acute sequelae of SARS-CoV-2 cardiovascular syndrome (PASC-CVS) were included prospectively into the Vienna POSTCOV Registry between March 2021 and March 2023 (clinicaltrials.gov NCT05398952). Clinical, laboratory, and CMR findings were recorded. Patients with abnormal CMR results were classified into isolated chronic pericardial (with/without pleural) effusion, isolated cardiac function impairment, or both (myopericarditis) groups. Medical treatment included a nonsteroidal anti-inflammatory agent (NSAID) for pericardial effusion and a condition-adapted maximal dose of heart failure (HF) treatment. Three months after medical therapy, clinical assessment and CMR were repeated in 82 patients. Laboratory analyses revealed normal hematological, inflammatory, coagulation, and cardiac biomarkers. CMR abnormalities were found in 155 patients (55.8%). Condition-adapted HF treatment led to a significant increase in the left ventricular ejection fraction (LVEF) in patients with initially reduced LVEF (from 49 ± 5% to 56 ± 4%, p = 0.009, n = 25). Low–moderate doses of NSAIDs for 3 months significantly reduced pericardial effusion (from 4/3;5.75/mm to 2/0;3/mm, median/interquartile ranges/p &lt; 0.001, n = 51). Clinical symptoms improved markedly with a decrease in CMR abnormalities, which might be attributed to the maintenance of NSAID and HF medical treatment for PASC-CVS.</jats:p>
  • Access State: Open Access